scispace - formally typeset
B

Bernhard Tribukait

Researcher at Karolinska Institutet

Publications -  180
Citations -  5461

Bernhard Tribukait is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Carcinoma & Dysplasia. The author has an hindex of 44, co-authored 178 publications receiving 5372 citations. Previous affiliations of Bernhard Tribukait include Mansoura University & University of Maryland, Baltimore.

Papers
More filters
Journal ArticleDOI

Prognostic significance of flow-DNA analysis and cell surface isoantigens in carcinoma of bilharzial bladder

Atallah A. Shaaban, +11 more
- 01 Mar 1992 - 
TL;DR: The most significant prognostic indicators were the DNA index and the status of the pelvic lymph nodes at operation and the ABO(H) isoantigen status, which did not correlate with pathologic parameters or the clinical course of these invasive bilharzial bladder tumors.
Journal ArticleDOI

Predicting invasiveness and disease-specific survival in upper tract urothelial carcinoma: identifying relevant clinical tumour characteristics.

Camilla Malm, +6 more
- 23 Apr 2019 - 
TL;DR: Grade, DNA ploidy and S-phase fraction were the only tumour characteristics associated with stage in this study, however, DNA Ploidy was not associated with DSS.
Journal ArticleDOI

DNA pattern of human pituitary tumors.

Matti Anniko, +1 more
- 01 Mar 1985 - 
TL;DR: Most tumors with an aggressive clinical course were either aneuploid or diploid but with a high percentage of proliferating cells, including pituitary adenomas with two cell lines and all but one hypodiploid tumor.
Journal ArticleDOI

Reliability of DNA cytometric S-phase analysis in surgical biopsies: assessment of systematic and sampling errors and comparison between results obtained by image and flow cytometry.

Thomas Heiden, +2 more
- 15 Jun 2000 - 
TL;DR: Tests in histograms obtained from surgical biopsies by flow cytometry showed that the background subtraction is reliable if the found S-phase fraction is higher than the fraction of background events in the histogram range of the cell population.
Patent

Predicting cancer progression

Sven Skog, +3 more
TL;DR: The binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of progress of the cancer disease is estimated based directly on this determined IM binding response levels as discussed by the authors.